COTA Inc., a leader in real-world data (RWD) and analytics for oncology, has announced a new partnership with precision oncology company Guardant Health Inc. (Nasdaq: GH). This collaboration will provide biopharmaceutical researchers with access to COTA’s research-grade electronic health record (EHR) data from academic and community care centers, alongside Guardant’s clinicogenomic testing data. Together, the partnership aims to accelerate the development of new cancer therapies.
COTA Inc., a leader in real-world data (RWD) and analytics for oncology, has teamed up with Guardant Health Inc., a precision oncology company, to offer biopharmaceutical researchers access to combined resources for accelerating cancer therapy development. The partnership merges COTA’s research-grade electronic health record (EHR) data from academic and community care centers with Guardant’s clinicogenomic testing data. This collaboration aims to deepen insights into the correlations between molecular biomarkers, treatment decisions, and clinical outcomes, helping to optimize drug development and accelerate cancer treatment programs across diverse patient populations.
By leveraging this extensive dataset and AI analytics, research scientists can more easily test hypotheses and validate the effectiveness of targeted therapies based on patient genomic profiles and real-world outcomes. This data, including critical longitudinal serial testing information, can significantly enhance biomarker discovery, refine clinical trials, and speed up drug approvals, ultimately improving cancer treatment for a wide range of patients.
Dr. C.K. Wang, Chief Medical Officer at COTA, explained, “Clinicogenomic data empowers researchers to test hypotheses by analyzing genomic profiles and real-world outcomes, guiding the development of personalized therapies for cancer patients.” By integrating Guardant’s data with COTA’s comprehensive real-world oncology data, the collaboration will help anticipate treatment responses and accelerate drug development for both new and existing patient populations.
The drug development process is often lengthy, taking up to fifteen years, and with 97% of cancer clinical trials failing, there is a growing investment in multi-modal data sets like clinicogenomics. By analyzing how patient populations respond to therapies in real-world settings, drug developers can better design clinical trials, identify biomarkers, and bring targeted treatments to market faster.
Craig Eagle, MD, Chief Medical Officer at Guardant Health, stated, “Our partnership with COTA marks another milestone in our mission to conquer cancer with data. Connecting tumor biology and therapy response data with real-world patient outcomes will accelerate the discovery of new biomarker-based therapies and make the drug development process more efficient.”
Guardant’s real-world longitudinal serial testing data covers all stages of cancer, from initial tumor profiling for therapy selection to recurrence and therapy monitoring. COTA’s curated data, tracking a patient’s complete cancer journey, enhances this by incorporating both academic and community care centers. This collaboration expands COTA’s data into solid tumors, such as lung, breast, and colorectal cancers, providing a broader, more diverse dataset with greater clinical insights.
About COTA, Inc.
COTA leverages real-world data to provide precise, patient-first cancer care, offering high-quality oncology data and advanced analytics to ensure optimal treatment paths.
About Guardant Health
Guardant Health is transforming cancer care by providing critical insights through blood and tissue tests, real-world data, and AI analytics, improving patient outcomes and accelerating new cancer therapies.
